Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Enhertu Nabs EU Nod for Second-Line Gastric Cancer, CHMP OK for HER2 Low Breast Cancer
December 20, 2022
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- R&D Head Shiro Akinaga Becomes NanoCarrier President
December 19, 2022
- SymBio, Eagle Pharma Sue Towa over Treakisym Patent in Japan
December 19, 2022
- Sosei, Lilly in Drug Discovery Collab for Diabetes and Metabolic Diseases
December 19, 2022
- Astellas’s Zolbetuximab Makes Marks in Another PIII Gastric Cancer Study
December 19, 2022
- Pharma Industry Mixed on Off-Year Drug Price Revision Plan for FY2023
December 19, 2022
- PeptiDream, Takeda Expected to Select 1st Oligo-PDC Candidate in 2023
December 16, 2022
- Eisai, Washington University to Team Up on Neurodegenerative Disease Therapies
December 16, 2022
- Twymeeg Most Promoted Drug in GP Market for 4 Months Straight in October: Intage
December 16, 2022
- Sunovion Offloads Lunesta to Woodward Pharma
December 16, 2022
- Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan: Exec
December 15, 2022
- Daiichi Sankyo Plots Further Growth with Enhertu Follow-Ons, Eyes Next-Gen ADCs
December 15, 2022
- Bayer Files Xarelto for Congenital Heart Disease after Fontan Procedure in Japan
December 15, 2022
- Total Sales of 25 Japan Drug Makers Up 12.9% in 1st Half, Global Players Fare Well While SMEs Falter
December 15, 2022
- Ono, PrecisionLife Ink Multi-Target R&D Collab
December 15, 2022
- Bribery Scandal Emerges for Hiroshima University Doctor over Ono’s Glactiv
December 14, 2022
- Takeda Puts Up US$4 Billion for Nimbus’ TYK2 Immune Therapy
December 14, 2022
- Chugai’s Appeal Bid for Edirol Method-of-Use Patent Dismissed
December 14, 2022
- NDA for Cefiderocol Accepted in Taiwan: Shionogi
December 14, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…